628686-89-5Relevant articles and documents
C-5 SUBSTITUTED QUINAZOLINONE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR BETA MODULATORS
-
Page/Page column 19, (2010/11/24)
The present application describes compounds according to Formula (I), wherein Q, R1, R2 and X are described herein, that are useful as Estrogen Receptor Beta (ERβ) modulators. Additionally, the present application describes pharmaceutical compositions containing the compounds according to Formula (I) and optionally additional therapeutic agents. Finally, the present application describes methods utilizing the compounds according to Formula (I) for modulating the function of ERβ in the treatment of diseases and disorders associated with ERβ such as, for example, bone disorders; cardiovascular diseases; hypercholesterolemia; hypertriglyceridemia; vasomotor disorders; urogenital disorders; prostatic hypertrophy; endometrial hyperplasia; cancer and central nervous system disorders, such as, neurodegenerative disorders.
3-ARYLQUINAZOLINE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR BETA MODULATORS
-
, (2019/03/15)
Novel quinazoline derivatives possessing activity as estrogen receptor beta (ERβ) modulators are provided which have the general formula I wherein X is O or S; A and B are each independently CR'" or N; R, R' and R" are each independently hydrogen, alkyl, benzyl, p-methoxybenzyl, allyl, or Si(R4) 3, wherein at least one of R, R' and R" is hydrogen; R'" is hydrogen, halogen, CF3, OR5, S(O)nR6, NR7R8, cycloalkyl or alkyl; R1, R2 and R3 are each independently hydrogen, halogen, CF 3, OR5, S(O)nR6, NR7R8, cycloalkyl or alkyl; R4 is a alkyl; R5, R6, R7 and R8 in each functional group are each independently hydrogen, cycloalkyl or alkyl; and n is an integer from 0 to 2. In addition, a method is provided for preventing, inhibiting or treating the progression or onset of pathological conditions associated with the estrogen receptor and to pharmaceutical compositions containing such compounds. "